Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021001601 - METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE

Publication Number WO/2021/001601
Publication Date 07.01.2021
International Application No. PCT/FI2020/050475
International Filing Date 30.06.2020
IPC
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 31/50 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
Applicants
  • ORION CORPORATION [FI]/[FI]
Inventors
  • LEVIJOKI, Jouko
  • PAPPINEN, Sari
  • SALORANTA, Lasse
Agents
  • ORION CORPORATION
Priority Data
2019559501.07.2019FI
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE
(FR) PROCÉDÉS D'ADMINISTRATION DE(R)-N-[4-(1,4,5,6-TÉTRAHYDRO-6-OXO-3-PYRIDAZINYL)PHÉNYL]ACÉTAMIDE
Abstract
(EN)
The invention relates to ocular, intranasal, oromucosal or pulmonary administration of (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide (I) for the treatment of diseases and conditions where, for example, inotropic, vasodilatory or calcium sensitizing effects are desired. The invention also relates to pharmaceutical dosage forms adapted for ocular, intranasal, oromucosal or pulmonary administration comprising (R)-N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide (I) as an active ingredient.
(FR)
L'invention concerne l'administration oculaire, intranasale, oromuqueuse ou pulmonaire de (R)-N-[4-(1,4,5,6-tétrahydro-6-oxo-3-pyridazinyl)phényl]acétamide (I) pour le traitement de maladies et d'affections dans lesquelles, par exemple, des effets inotropes, vasodilatateurs ou sensibilisateurs au calcium sont souhaités. L'invention concerne également des formes posologiques pharmaceutiques adaptées pour une administration oculaire, intranasale, oromuqueuse ou pulmonaire comprenant du (R)-N-[4-(1,4,5,6-tétrahydro-6-oxo-3-pyridazinyl)phényl]acétamide (I) en tant que principe actif.
Latest bibliographic data on file with the International Bureau